MiR-196a Is Specifically Regulated in FDG-PET Positive and Negative Small Intestinal Neuroendocrine Tumor Patients at Late Stage of Disease

#1412

Introduction: This collaborative research plan aims at elucidating the glycolytic metabolism in advanced FDG-PET positive (+) and FDG-PET negative (-) small intestinal neuroendocrine tumor (SI-NET) patients treated with Lutetium peptide receptor radionuclide therapy (177Lu-PRRT).

Aim(s): To identify a potential specific regulation of miR-196a in FDG-PET+ and FDG-PET- SI-NET patients at a late stage of disease.

Materials and methods: Total RNA of serum samples was isolated from 15 SI-NET samples (3 healthy donors Ctrl, 3 FDG-PET+ pre-177Lu-PRRT, 3 FDG-PET+ post-177Lu-PRRT, 3 FDG-PET- pre-177Lu-PRRT and 3 FDG PET- post-177Lu-PRRT) using the mirVana Paris Kit. Total RNA was converted to cDNA using TaqMan MicroRNA Reverse Transcription (RT) Kit. Pre-amplification was performed after the RT process to increase the sensitivity of target gene expression.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Giandomenico V

Authors: Giandomenico V, Li S, Lind T, Boccherini M, Skogseid B,

Keywords: glycolytic metabolism, peptide receptor radionuclide therapy (PRRT), serum samples, miRNA, FDG-PET positive and-PET negative SI-NET patients,